Skip to content
StockMarketAgent
Direct answer
ALNY trades against a final fair-value range of $387.78-$974.55, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $388, high $975, with mid-point at $666.
Stock analysis

ALNY ALNY fair value $388–$975

ALNY
By StockMarketAgent.AI team· supervised by
Przeanalizowano: 2026-05-13Następna aktualizacja: 2026-08-13Methodology v2.5Review: automatedArchetype: Hyper-growth
View archive
Cena
$292.03
▲ +373.72 (+127.97%)
Wartość godziwa
$666
$388–$975
Rekomendacja
Zdecydowanie kupuj
confidence 86/100
Potencjał wzrostu
+128.0%
upside to fair value
Margines Bezpieczeństwa
$565.89
MoS level · 15%
Kapitalizacja
$39.0B
P/E fwd 21.0
Awaryjny angielskiPL
Pokazujemy źródło angielskie podczas tłumaczenia
Ten raport nie został jeszcze przetłumaczony. Odśwież za kilka minut, gdy kolejka tłumaczeń go przetworzy.

§1 Podsumowanie wykonawcze

  • Composite fair value $666 with high case $975.
  • Implied upside of 128.0% to fair value.
  • Moat 9/10 · confidence 86/100 · Hyper-growth.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$666
Margin of safety
+56.1%
Confidence
86/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$292.03Price
Low $387.78
Mid $665.75
High $974.55

ALNY trades against a final fair-value range of $387.78-$974.55, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • First-mover advantage and foundational IP
    First-mover advantage and foundational IP in RNA interference.
  • Established commercial infrastructure across global
    Established commercial infrastructure across global rare disease markets.
  • Bull thesis
    The market is pricing ALNY as a mature rare-disease biotech rather than an inflecting hyper-growth platform.

§2 Scenariusz negatywny

Under an extreme stress test where the prevalent disease pipeline yields zero commercial value, ALNY reverts to a mature rare-disease biotech. This drops terminal multiples to 15x and compresses peak margins to 25%, resulting in our $387 bear caseBear caseThe worst-realistic outcome — what happens if our top three risks materialize together. Used to set the floor of our fair-value range and inform position sizing. floor.

Jak ta teza może się załamać

Prevalent Disease Pipeline Failure

25%· Medium

Key prevalent indication readouts, such as hypertension or obesity, fail to show superiority, restricting TAM strictly to rare diseases.

FV impact
Compresses valuation to $387 floor.
Trigger
12-24 months

Margin Squeeze from Pricing Pressure

· Medium

IRA and competitive pressure limit peak operating margins below the projected 35%, trapping the firm in a lower-return profile.

FV impact
Drops valuation to $480 FCFF DCF baseline.
Trigger
24-36 months

Genetic Medicine Disruption

· Low

CRISPR and base editing therapies permanently cure indications ALNY currently manages chronically, destroying chronic recurring revenue streams.

FV impact
Terminal growth drops to 0%, valuation below $300.
Trigger
5+ years
Sygnały wczesnego ostrzegania do monitorowania
WskaźnikBieżącyPróg wyzwalania
Delay or failure in Zilebesiran clinical readouts.MonitorDeterioration versus the report thesis
Operating margins failing to expand toward the 35% target.MonitorDeterioration versus the report thesis
R&D expanding disproportionately to revenue growth.MonitorDeterioration versus the report thesis
Increased competitive trial data from gene-editing peers.MonitorDeterioration versus the report thesis
Unexpected regulatory pushback on novel delivery mechanisms.MonitorDeterioration versus the report thesis

§3 Historia finansowa

Rachunek zysków i strat — ostatnich sześć okresów
PozycjaT−0T−1T−2T−3CAGR
Okres2022-12-312023-12-312024-12-312025-12-31Trend
Przychody$1.04B$1.83B$2.25B$3.71B+53.0%
Zysk brutto$868.6M$1.52B$1.92B$3.03B+51.7%
Zysk operacyjny$-785.1M$-282.2M$-176.9M$501.6M—
Zysk netto$-1.13B$-440.2M$-278.2M$313.7M—
EPS (rozwodniony)$-9.30$-3.52$-2.18$2.33—
EBITDA$-926.6M$-258.2M$-178.8M$631.4M—
R&D$883.0M$1.00B$1.13B$1.32B+14.3%
SG&A$770.7M$795.6M$975.5M$1.21B+16.3%

Wyniki jakości

OCF / Zysk netto
1.67×
>1 wskazuje wysoką jakość wyników
Bramka jakości księgowej
Fail
Bramka skorygowana o sektor
ROIC
22.0%
Zwrot z zainwestowanego kapitału
Sekcja 3

Numbers analysis

Przepływy pieniężne

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

Alokacja kapitału

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

Subskrybenci indywidualni — od §411 kolejnych sekcji

Przeczytaj pełną analizę — 11 kolejnych sekcji.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

Pełny raport dla każdego pokrytego tickera
24 miesiące archiwum rekomendacji
Briefingi watchlisty + alerty zmian rekomendacji
Eksport PDF + DOCX w dowolnym języku
Rozpocznij darmowy okres próbny
Anuluj w dowolnym momencie.
FAQ

ALNY — frequently asked questions

  1. Based on our latest analysis, ALNY looks meaningfully undervalued. The current price is $292 versus a composite fair-value midpoint of $666 (range $388–$975), which implies roughly 128.0% upside to the midpoint.

Related coverage

Names readers of ALNY also follow

Same archetype: hyper-growth